Stage III oesophageal squamous cell carcinoma is a serious condition where cancer has spread beyond the inner lining of the food pipe, sometimes reaching nearby tissues or lymph nodes. Treatment aims to control the disease, reduce symptoms, and help patients maintain the best possible quality of life, with approaches carefully tailored to each individual’s health and disease characteristics.

Understanding Treatment Goals and Options

When someone receives a diagnosis of stage III oesophageal squamous cell carcinoma, treatment decisions become both urgent and complex. At this stage, the cancer has grown through several layers of the oesophagus, which is the muscular tube connecting the throat to the stomach, and may have reached up to six nearby lymph nodes—small bean-shaped structures that help fight infection and disease. The cancer might also have spread into surrounding structures like the outer covering of the heart, the tissue covering the lungs, or the diaphragm muscle that helps with breathing. However, the disease has not yet travelled to distant parts of the body^[2][4].

The primary goals of treatment at this stage are multifaceted. Doctors work to eliminate as much cancer as possible, slow down its progression, relieve troubling symptoms like difficulty swallowing, and extend survival while preserving quality of life. Because stage III disease represents locally advanced cancer that hasn’t yet metastasized widely, there remains a window of opportunity for potentially curative treatment, though success depends on many factors including the patient’s overall health, the exact location of the tumour, and how well it responds to therapy^[5][8].

Treatment planning requires careful coordination among multiple specialists. An interdisciplinary tumour board—a team of oncologists, surgeons, radiation specialists, pathologists, and nutritionists—typically reviews each case to recommend the most appropriate approach. This collaborative decision-making ensures that all aspects of a patient’s condition are considered before treatment begins. Importantly, patients themselves play a central role in these decisions, as treatment preferences, lifestyle considerations, and personal values all influence the final plan^[14].

Standard medical societies and cancer organizations have established treatment guidelines based on years of research and clinical experience. However, alongside these established therapies, ongoing clinical trials continue to test new approaches that may one day become standard care. Some patients may have the opportunity to participate in these research studies, gaining early access to innovative treatments while contributing to medical knowledge^[5][8].

Standard Treatment Approaches

Chemotherapy and Radiation Therapy Combined

For stage III oesophageal squamous cell carcinoma, the most widely used standard treatment involves combining chemotherapy and radiation therapy, a strategy called chemoradiation. In this approach, both treatments are delivered during the same time period rather than one after the other. The chemotherapy drugs make cancer cells more sensitive to radiation, while the radiation beams target the tumour directly. This dual attack increases the chance of destroying cancer cells while they’re most vulnerable^[8][10].

Chemoradiation can be given in different scenarios. Many patients receive it before surgery as neoadjuvant therapy, which means treatment delivered first to shrink the tumour and make surgical removal easier and more complete. Others may receive it after surgery as adjuvant therapy to eliminate any remaining cancer cells. For patients whose overall health makes surgery too risky, or for those who choose not to undergo surgery, chemoradiation can serve as the main treatment on its own^[8][10].

The chemotherapy medications most commonly used for stage III disease include several active substances, often given in combinations. Cisplatin, a platinum-based drug, is frequently paired with fluorouracil (also called 5-FU), which interferes with cancer cell growth. Another common combination uses carboplatin with paclitaxel, which works by preventing cancer cells from dividing. Some regimens include three drugs together, such as epirubicin, cisplatin, and fluorouracil. Additional options include combinations with capecitabine (an oral form of fluorouracil), oxaliplatin, docetaxel, irinotecan, or etoposide^[8][10].

The duration of chemotherapy treatment varies depending on the specific regimen and whether it’s given before or after surgery. Neoadjuvant chemoradiation typically lasts several weeks, with chemotherapy cycles repeated every few weeks. The radiation therapy portion usually involves daily treatments over several weeks, carefully calculated to deliver enough energy to damage cancer cells while minimizing harm to surrounding healthy tissues^[8].

Surgical Treatment

Surgery remains an important component of treatment for many patients with stage III oesophageal squamous cell carcinoma, particularly when combined with chemoradiation. The surgical procedure, called an oesophagectomy, involves removing the cancerous portion of the oesophagus and some surrounding tissue, then reconnecting the remaining oesophagus to the stomach or using a piece of intestine to bridge the gap. This is major surgery requiring significant recovery time, but it offers the possibility of completely removing visible cancer^[8][13].

However, not every patient with stage III disease is a candidate for surgery. The decision depends on several factors including the tumour’s exact location, whether it has grown into critical nearby structures, the patient’s lung and heart function, overall fitness level, and other medical conditions. For tumours located in the cervical (neck) portion of the oesophagus, surgery is particularly challenging and doctors often recommend definitive chemoradiation without surgery instead^[14][16].

Managing Side Effects

Both chemotherapy and radiation therapy cause side effects that require proactive management. Chemotherapy commonly causes nausea, vomiting, fatigue, increased infection risk due to low white blood cell counts, and potential damage to nerves causing tingling or numbness in hands and feet. Different drugs have different side effect profiles—for instance, cisplatin can affect kidney function and hearing, while paclitaxel more commonly causes nerve damage^[8].

Radiation to the oesophagus and surrounding chest area causes its own set of challenges. Patients typically experience worsening difficulty swallowing as treatment progresses, sometimes developing painful inflammation of the oesophagus called oesophagitis. Fatigue accumulates over the treatment course. Radiation can also irritate the lungs, causing cough or shortness of breath, and may affect the heart over time. These side effects usually peak toward the end of treatment and in the weeks immediately following, then gradually improve, though some effects can persist^[8].

Medical teams use various strategies to minimize and manage these side effects. Anti-nausea medications help control chemotherapy-induced sickness. Growth factors can stimulate white blood cell production to reduce infection risk. Pain medications, swallowing aids, and nutritional support help patients maintain adequate intake despite oesophagitis. Close monitoring allows early detection and treatment of complications before they become serious^[24].

Immunotherapy as a New Standard

One of the most significant recent advances in treating oesophageal squamous cell carcinoma involves immunotherapy—medications that help the body’s own immune system recognize and attack cancer cells. Unlike chemotherapy, which directly poisons rapidly dividing cells, immunotherapy works by removing the “brakes” that cancer cells place on immune responses, allowing immune cells to do their natural job of destroying abnormal cells^[8][10].

Pembrolizumab, marketed as Keytruda, represents one such immunotherapy drug approved for stage III oesophageal squamous cell carcinoma. It belongs to a class called checkpoint inhibitors, specifically targeting a protein called PD-1 on immune cells. When pembrolizumab blocks this protein, it prevents cancer cells from hiding from the immune system. For squamous cell carcinoma of the oesophagus, pembrolizumab may be offered in combination with cisplatin and fluorouracil as first-line treatment^[8][10].

Another immunotherapy option is nivolumab (Opdivo), which works similarly by blocking the PD-1 checkpoint. Nivolumab may be offered if cancer remains after neoadjuvant chemoradiation and surgery, helping eliminate residual disease. It can also be combined with standard chemotherapy drugs like cisplatin and fluorouracil or carboplatin and fluorouracil^[8][10].

A particularly important application of immunotherapy occurs after surgery for patients who received neoadjuvant chemoradiation. When examination of the surgically removed tissue shows that not all cancer cells were destroyed by the preoperative treatment—meaning there wasn’t a complete pathological response—adjuvant immunotherapy for up to one year has been shown to improve disease-free survival. This approach helps prevent cancer from returning^[14][16].

Immunotherapy causes a different side effect profile compared to traditional chemotherapy. Rather than causing hair loss and severe nausea, these drugs can trigger immune-related adverse events where the activated immune system attacks normal body tissues. This might affect the skin (causing rashes), digestive tract (causing diarrhea or colitis), lungs (causing inflammation), or hormone-producing glands (affecting thyroid, pituitary, or adrenal function). While these effects can be serious, they’re generally manageable with corticosteroids and close monitoring^[8][14].

Treatment in Clinical Trials

While the standard treatments described above represent current best practice, researchers continuously work to develop better therapies through clinical trials. These carefully designed research studies test new drugs, new combinations of existing drugs, or innovative treatment strategies. For patients with stage III oesophageal squamous cell carcinoma, participating in a clinical trial may provide access to cutting-edge treatments before they become widely available^[5][14].

Understanding Clinical Trial Phases

Clinical trials progress through distinct phases, each with specific goals. Phase I trials primarily assess safety, determining the appropriate dose of a new treatment and identifying potential side effects in a small group of patients. Phase II trials expand to larger groups to evaluate whether the treatment actually works against the cancer and to gather more safety information. Phase III trials compare the new treatment directly against current standard therapy in large patient populations, often involving hundreds or thousands of participants across multiple institutions or countries. Only treatments that successfully complete these phases gain approval for routine use^[5].

Innovative Immunotherapy Combinations

Many current clinical trials for oesophageal squamous cell carcinoma explore ways to make immunotherapy more effective. One approach combines different checkpoint inhibitors together. For example, ipilimumab (Yervoy) blocks a different checkpoint protein called CTLA-4, and trials are testing whether combining ipilimumab with nivolumab provides better results than either drug alone. The combination potentially attacks cancer through multiple immune pathways simultaneously^[8][10].

Other trials investigate combining immunotherapy with targeted therapies. While immunotherapy broadly activates the immune system, targeted therapies attack specific molecular vulnerabilities in cancer cells. Combining these approaches might work synergistically, with targeted therapy making tumours more visible to immune system attack while immunotherapy provides the attacking force^[14].

Targeted Therapy Development

Although stage III oesophageal squamous cell carcinoma trials focus heavily on immunotherapy, researchers also investigate targeted therapies that block specific proteins cancer cells need to grow and survive. These drugs work differently from traditional chemotherapy by specifically targeting molecular pathways that cancer cells depend on more than normal cells do^[8][14].

Some trials examine drugs that block growth factor receptors—proteins on cancer cell surfaces that receive signals telling cells to grow and divide. By blocking these receptors, targeted therapies can slow cancer progression. Other studies test inhibitors of angiogenesis, the process by which tumours develop new blood vessels to supply themselves with oxygen and nutrients. Without adequate blood supply, tumours cannot grow beyond a certain size^[14].

Novel Radiation Techniques

Clinical trials also evaluate improved radiation therapy methods. Proton therapy uses proton beams instead of traditional X-rays to deliver radiation. Protons can be controlled more precisely, depositing most of their energy directly in the tumour with minimal exit dose beyond, potentially reducing damage to surrounding healthy tissues like the heart, lungs, and spinal cord. Trials compare whether this precision translates into fewer side effects and better outcomes^[16].

Another area of investigation involves using imaging techniques to adapt radiation treatment in real-time based on how the tumour responds. Called adaptive radiotherapy, this approach allows doctors to modify the radiation plan during the treatment course if scans show the tumour shrinking or changing shape, ensuring optimal targeting throughout therapy^[16].

Participation and Eligibility

Clinical trials for stage III oesophageal squamous cell carcinoma are conducted at cancer centres throughout the United States, Europe, and other regions. Each trial has specific eligibility criteria regarding disease stage, prior treatments, overall health status, and other factors. Patients interested in clinical trials should discuss options with their oncology team, who can help identify appropriate studies and explain potential benefits and risks^[5].

Trial participation involves additional testing and monitoring compared to standard treatment, with more frequent visits and assessments. Patients typically receive the investigational treatment at no cost, though other medical care expenses may not be covered. Importantly, participation is entirely voluntary, and patients can withdraw at any time without affecting their right to receive standard care^[5].

Most common treatment methods

• Chemoradiation (Combined Chemotherapy and Radiation Therapy)
  • Given as neoadjuvant therapy before surgery to shrink tumours
  • Administered as adjuvant therapy after surgery to eliminate remaining cancer cells
  • Used as definitive treatment for patients not suitable for surgery
  • Involves multiple chemotherapy drugs like cisplatin, fluorouracil, carboplatin, paclitaxel, and others
  • Radiation delivered daily over several weeks concurrent with chemotherapy cycles
• Immunotherapy
  • Pembrolizumab (Keytruda) combined with cisplatin and fluorouracil as first-line treatment
  • Nivolumab (Opdivo) for residual disease after neoadjuvant therapy and surgery
  • Nivolumab combined with chemotherapy drugs for initial treatment
  • Ipilimumab (Yervoy) in combination with other immunotherapy agents
  • Adjuvant immunotherapy for up to one year after surgery when complete pathological response not achieved
• Surgical Treatment (Oesophagectomy)
  • Removal of cancerous portion of oesophagus with surrounding tissue
  • Reconstruction using stomach or intestinal segment
  • Typically performed after neoadjuvant chemoradiation
  • Not recommended for cervical oesophageal tumours
  • Requires careful patient selection based on overall health and tumour characteristics
• Chemotherapy Alone
  • May be offered without radiation therapy before surgery for some stage III tumours
  • Common regimens include combinations of capecitabine, cisplatin, fluorouracil, carboplatin, paclitaxel, epirubicin, docetaxel, oxaliplatin, irinotecan, and etoposide
  • Delivered in cycles with rest periods to allow body recovery
• Nutritional Support
  • Feeding tube placement before treatment begins
  • Helps patients maintain weight and adequate nutrition during therapy
  • Critical for completing full treatment course
  • Improves treatment tolerance and outcomes